HealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors. Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants. HealthQuest was joined in this investment by Arboretum Ventures and select insiders.
Trice Medical completes its first successful case performed in the United Kingdom, after receiving CE Mark of approval in Europe for the mi-eye 2™, as well as entry into Health Canada.
HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft. NeoGraft is an industry leader in the area of hair restoration technologies. Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.
HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software. HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.
Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
HealthQuest Capital Managing Partner, Dr. Garheng Kong, was selected as one of 21 healthcare industry leaders to participate in the Aspen Insitute's Health Innovators Fellowship. He and the other fellows will participate in a two-year Fellowship designed to strengthen the leadership of innovators across the US health care ecosystem and challenge them to create new approaches to improve the health and well-being of all Americans.
Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has entered into a definitive agreement to acquire Spirox, Inc., a privately-held ENT medical technology company that develops, manufactures and markets the LATERA™ Absorbable Nasal Implant, a minimally invasive option for ENTs and facial plastic surgeons to treat nasal airway obstruction.
Biotheranostics, Inc. today announced new data from two new studies further demonstrating the importance of BCI in clinical practice. The studies are being presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago this week.
Trice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company's U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN) has taken a minority stake joining a consortium of current investors including HealthQuest.
Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners.
Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates whether a technology could improve net health outcomes
Vesey Street Capital Partners, LLC (VSCP) today announced the completed recapitalization of HealthChannels (parent company of ScribeAmerica), a healthcare services organization with a full suite of solutions that enhances provider productivity, streamlines clerical processes and improves health outcomes. With 13,000 employees across 50 states and three countries, HealthChannels is uniquely positioned to help providers meet increased demands around mission-critical activities ranging from electronic medical records documentation to patient navigation, medical billing and coding. HealthQuest Capital and Heritage Group joined Vesey Street in the financing.
Avizia, the leading end to end telehealth solution provider, today announced the completion of its Series A financing totaling $17 million. The company raised an additional $6 million to supplement the initial $11 million, which was announced in July 2016. HealthQuest Capital led the additional round which included investment from strategic partner NewYork-Presbyterian.
Trice Medical announced today that it received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for mi-eye 2, a disposable needle with a fully integrated camera that enables physicians to use advanced diagnostic imaging to visualize joint injuries in their clinic.
Magnolia Medical Technologies, developer of the SteriPath® blood collection system and leader in improving the quality and accuracy of in-vitro diagnostic test results, today announced the closing of the company's $13.8 million Series B financing led by HealthQuest Capital. In conjunction with the financing, Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest Capital will join the company's board.
VirMedica, the leader in providing e-access and specialty pharmacy technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of three new executives to the Company's senior leadership team. John J. Arcari has been appointed to chief financial officer (CFO) and will oversee the Company's financial operations. Richard Deyermond joins the company as vice president of client services and will lead teams engaged in the delivery of VirMedica's technology solutions. As the vice president of engineering, Elizabeth Ricci will focus on building out the Company's technology suite.